托伐普坦早期与延迟治疗常染色体显性多囊肾病的长期疗效与安全性:TEMPO 4:4 多中心开放标签延伸试验
TEMPO 4:4 是 TEMPO 3:4 的延伸试验,纳入完成 3:4 的受试者继续观察托伐普坦长期疗效与安全性。结果显示 eGFR 获益持续(3.15 mL/min/1.73 m2,P < 0.001)且斜率非劣,但 TKV 的持续治疗差异未获证实,安全性特征与 3:4 相似。
要点
- 托伐普坦对 eGFR 的改善作用在延伸期持续存在
- TKV 的组间持续差异未获证实,可能与设计局限有关
- 延伸期安全性特征与 TEMPO 3:4 相似
核心结论
- TEMPO 4:4 结果支持托伐普坦对 eGFR 具有持续性的疾病修饰作用。
- TKV 未见持续治疗差异,可能归因于试验设计局限,包括随机化丢失及 TEMPO 3:4 后的基线失衡。
- 延伸期托伐普坦安全性特征与 TEMPO 3:4 相似。
研究设计与样本
- TEMPO 4:4 为多中心、开放标签延伸试验,旨在为完成 TEMPO 3:4 的受试者额外提供 2 年托伐普坦长期安全性与疗效数据。
- TEMPO 3:4 随机分配 1445 例受试者,其中 871 例(60.3%)入组 TEMPO 4:4。
- 评估终点包括从基线至 TEMPO 3:4 与 TEMPO 4:4 合计期间 TKV 与 eGFR 的变化,以及 TEMPO 4:4 期间斜率的非劣性。
主要发现
- TEMPO 3:4 基线至 TEMPO 4:4 第 24 月 TKV 变化百分比为 29.9% 与 31.6%(既往托伐普坦组 vs 既往安慰剂组,P = 0.38)。
- 校正基线协变量后,TEMPO 4:4 第 24 月 TKV 治疗差异由 -1.70% 改善至 -4.15%(P = 0.04)。
- TEMPO 4:4 期间 TKV 增长斜率在早期治疗组高于延迟治疗组(6.16%/年 vs 4.96%/年,P = 0.05)。
- 次要 eGFR 终点分析显示对 eGFR 的持续效应(3.15 mL/min/1.73 m2,P < 0.001),且 eGFR 斜率非劣。
临床怎么用
- 对于常染色体显性多囊肾病,托伐普坦对 eGFR 的获益可在延伸治疗中持续,支持长期用药以延缓肾功能下降。
- 解读 TKV 结果时需考虑延伸试验开放标签、随机化丢失与基线失衡带来的偏倚,不宜据此否定早期治疗。
局限性
- 开放标签延伸设计且随机化丢失,基线存在失衡。
- TKV 的持续治疗差异未获证实,作者归因于试验设计局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In TEMPO 3:4, the vasopressin V2 receptor antagonist tolvaptan slowed total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline relative to placebo. METHODS: TEMPO 4:4 was designed to provide an additional 2 years of data on the long-term safety and efficacy of tolvaptan in subjects completing TEMPO 3:4. The objective was to assess the disease-modifying effects of tolvaptan on TKV and eGFR end-points including change from baseline over the combined duration of TEMPO 3:4 and TEMPO 4:4, and non-inferiority of slopes during TEMPO 4:4. RESULTS: Of the 1445 subjects randomized to TEMPO 3:4, 871 (60.3%) enrolled in TEMPO 4:4. Percent changes in TKV from TEMPO 3:4 baseline to TEMPO 4:4 Month 24 were 29.9% and 31.6% (prior tolvaptan versus prior placebo, P = 0.38). Adjusting for baseline covariates improved the TKV treatment difference at Month 24 in TEMPO 4:4 from -1.70% to - 4.15% between the groups (P = 0.04). Slopes of TKV growth during TEMPO 4:4 were higher in early- versus delayed-treatment groups (6.16% versus 4.96% per year, P = 0.05). Analysis of secondary eGFR endpoints demonstrated a persistent effect on eGFR (3.15 mL/min/1.73 m2, P < 0.001), and non-inferiority in eGFR slopes. The safety profile on exposure to tolvaptan in TEMPO 4:4 was similar to that in TEMPO 3:4. CONCLUSIONS: The results of TEMPO 4:4 support a sustained disease-modifying effect of tolvaptan on eGFR. The lack of a sustained treatment difference on TKV may be accounted for by limitations of the trial design, including loss of randomization and baseline imbalances ensuing TEMPO 3:4. The safety profile was similar to that observed in TEMPO 3:4.
引用
- Torres VE, Chapman AB, Devuyst O, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018. PMID: 28379536. doi:10.1093/ndt/gfx043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。